(NASDAQ: CERT) Certara's forecast annual revenue growth rate of 17.33% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.5%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.23%.
Certara's revenue in 2023 is $324,357,000.On average, 4 Wall Street analysts forecast CERT's revenue for 2023 to be $60,143,229,415, with the lowest CERT revenue forecast at $58,611,167,009, and the highest CERT revenue forecast at $61,027,019,453. On average, 3 Wall Street analysts forecast CERT's revenue for 2024 to be $70,837,807,408, with the lowest CERT revenue forecast at $68,951,590,295, and the highest CERT revenue forecast at $73,465,545,920.
In 2025, CERT is forecast to generate $84,977,969,003 in revenue, with the lowest revenue forecast at $84,977,969,003 and the highest revenue forecast at $84,977,969,003.